NASDAQ:FDMT

4D Molecular Therapeutics Q3 2026 Earnings Results & Report

4D Molecular Therapeutics logo
$10.62 +0.16 (+1.53%)
As of 02:46 PM Eastern
This is a fair market value price provided by Massive. Learn more.

4D Molecular Therapeutics missed analyst earnings expectations but beat on revenue in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$1.08 versus the -$1.05 consensus estimate, while revenue of $4.15 million topped the $4.13 million estimate by $12.00 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
7:00 AM ET

4D Molecular Therapeutics EPS Results

Actual EPS
-$1.08
Consensus EPS
-$1.05
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

4D Molecular Therapeutics Revenue Results

Actual Revenue
$4.15 million
Expected Revenue
$4.13 million
Beat/Miss
Beat by +$12.00 thousand
YoY Revenue Growth
N/A

4D Molecular Therapeutics Q3 2026 Earnings FAQ

4D Molecular Therapeutics (NASDAQ:FDMT) reported earnings of -$1.08 per share for Q3 2026, missing the consensus estimate of -$1.05. The report was announced on Thursday, November 12, 2026.

4D Molecular Therapeutics reported revenue of $4.15 million for Q3 2026, against a consensus estimate of $4.13 million.

4D Molecular Therapeutics Earnings Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
4DMT Announces New Employment Inducement Grants
See More 4D Molecular Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 4D Molecular Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 4D Molecular Therapeutics and other key companies, straight to your email.

About 4D Molecular Therapeutics

4D Molecular Therapeutics (NASDAQ:FDMT) is a biotechnology company developing genetic medicines for serious diseases. Its research focuses on adeno-associated virus (AAV) gene therapies, which use engineered viral vectors to deliver therapeutic genetic material to cells.

The company’s proprietary Therapeutic Vector Evolution platform is designed to create AAV vectors with targeted properties, including the ability to reach specific tissues. Its investigational programs have included treatments for retinal diseases, cystic fibrosis and Fabry disease.

Founded in 2013, 4D Molecular Therapeutics is based in Emeryville, California. Its work is focused on developing gene therapies, rather than marketing approved medicines.

View 4D Molecular Therapeutics Profile